The purpose of this study is to see if an HIV vaccine, AIDSVAX B/B, can protect adults who are at risk from becoming infected with HIV. Patients who become infected despite immunization will be studied to see if receiving the vaccine before becoming infected will help keep HIV levels (viral load) low.
Volunteers receive 7 blinded, intramuscular vaccinations (at Months 0, 1, 6, 12, 18, 24, 30) containing either the AIDSVAX B/B vaccine or a placebo (aluminum adjuvant only). Volunteers are randomized in a 2 to 1 vaccine-to-placebo ratio. HIV-uninfected persons are followed for a total of 16 visits beginning at screening and continuing until Month 36. Patients who become HIV infected during study are followed every 4 months for at least 24 months.
Study Type
INTERVENTIONAL
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
5,000
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Univ of Alabama at Birmingham
Birmingham, Alabama, United States
Phoenix Body Positive
Phoenix, Arizona, United States
Arizona Clinical Research Ctr Inc
Tucson, Arizona, United States
Univ of California / UCI Med Ctr
Orange, California, United States
ViRx Inc
Palm Springs, California, United States
Univ of California - Davis Med Ctr / CARES
Sacramento, California, United States
San Francisco Dept of Hlth / AIDS Office
San Francisco, California, United States
San Francisco Gen Hosp
San Francisco, California, United States
UCSF - San Francisco Gen Hosp
San Francisco, California, United States
Santa Clara Public Health Dept
San Jose, California, United States
...and 57 more locations